Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023
Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Management of Child-Pugh B Patients with Advanced HCC
Oncologists provide an overview of the treatment management of Child-Pugh B patients with advanced HCC.
Treatment Considerations for Advanced HCC in Second Line and Beyond
In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.
Systemic Immunotherapies for Advanced HCC in Second Line and Beyond
In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.
Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond
Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.
Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond
Oncologists review a patient profile, evaluating treatment approaches for patients with advanced HCC that have progressed beyond 1L treatment.
Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab
Experts discuss treatment options for patients unsuitable for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.
Real-World Evidence for Lenvatinib in Advanced HCC
Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.
Patient Profile 2: Advanced HCC Treated with Lenvatinib
A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.
Other Frontline Immunotherapy-based Combinations in Advanced HCC
Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.
Selecting the Appropriate Frontline Treatment in Advanced HCC
Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.
HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC
Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.
Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab
Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.
Patients With Intermediate Stage HCC Suitable for TACE
Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.
Patients With Intermediate Stage HCC Unsuitable for TACE
Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).
Patient Case: 63-Year-Old Woman With Advanced HCC
Drs Anthony B. El-Khoueiry, Daneng Li, Nicole Rich, and Pierre Gholam share treatment approaches for a 63-year-old woman who received an advanced HCC diagnosis with Child-Pugh A liver function.
How the Potential Use of Immunotherapy in Intermediate HCC Might Affect its Use in Advanced HCC
Dr Nicole Rich discusses immunotherapy and potential combinations in intermediate and advanced hepatocellular carcinoma.
Unmet Needs in the Treatment of Advanced HCC in Second-Line and Beyond
Key opinion leaders in gastrointestinal cancers provide insight on unmet needs and challenges in the treatment of advanced hepatocellular carcinoma in the second-line and beyond setting.
Sequencing Therapies After Frontline TKI Therapy in Advanced HCC
Experts in gastrointestinal cancers comment on their treatment approaches for patients with second-line advanced hepatocellular carcinoma who receive frontline TKI therapy.
Selecting the Appropriate Treatment in Second-Line and Beyond in Advanced HCC
Experts in gastrointestinal cancers share factors to consider when selecting the optimal second-line therapy for patients with advanced hepatocellular carcinoma.
Immunotherapies in Second-Line and Beyond in Advanced HCC
Pierre Gholam, MD, comments on systemic immunotherapy options for second-line and beyond treatment of advanced hepatocellular carcinoma.
Anti-Angiogenic Therapies in Second-Line and Beyond in Advanced HCC
Anthony B. El-Khoueiry, MD, reviews anti-angiogenic systemic therapy options for patients with advanced HCC in the second-line and beyond setting.
Is There a Role for Liver-Directed Therapy in Advanced HCC?
An expert gastroenterologist, Dr Pierre Gholam, discusses the phase 3 LAUNCH trial and shares insight on the potential role of liver-directed therapy in the treatment of advanced hepatocellular carcinoma.
Emerging Frontline Treatment Strategies in Advanced HCC
Daneng Li, MD, discusses novel regimens in the pipeline being evaluated for the treatment of frontline advanced HCC.
Is There a Role for Single-Agent Immunotherapy in Advanced HCC?
Experts in gastrointestinal cancers, Drs Pierre Gholam and Daneng Li, comment on the role of single-agent immunotherapy for first-line treatment of advanced HCC.
Frontline Therapies in Advanced HCC for Patients Unsuitable for Atezolizumab-Bevacizumab
Pierre Gholam, MD, considers the optimal treatment selection for patients in whom an atezolizumab-bevacizumab combination isn’t a suitable frontline therapeutic option.
Which Patients With HCC Are Suitable for Treatment With Atezolizumab and Bevacizumab?
Nicole Rich, MD, reviews the patient selection for atezolizumab-bevacizumab and discusses patients in whom this regimen is contraindicated in the frontline setting in advanced HCC.
Phase 3 HIMALAYA Study in Advanced HCC
Dr Daneng Li reviews updated safety and efficacy results of durvalumab plus tremelimumab from the phase 3 HIMALAYA study in frontline unresectable HCC.
Phase 3 COSMIC-312 Study in Advanced HCC
Daneng Li, MD, evaluates the use of cabozantinib plus atezolizumab in first-line advanced unresectable HCC as seen in the COSMIC-312 study.
First-Line Systemic Treatment for Advanced HCC
Anthony B. El-Khoueiry, MD, provides insight on the evolution of care for frontline systemic therapy in advanced HCC and discusses currently approved first-line standard of care options.
Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma
TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy
Liso-Cel Leads to Rapid Responses, High Undetectable MRD Rates in Relapsed/Refractory CLL/SLL
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC
2 Clarke Drive Cranbury, NJ 08512